Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETX101 gene therapy in SCN1A-positive Dravet syndrome
NCT06112275Phase 2Active, not recruiting
- Sponsor
- Encoded Therapeutics
- Start
- Feb 2024
- Primary completion
- Sep 2030
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of etx101 in Dravet syndrome, sponsored by Encoded Therapeutics. Started Feb 2024; status: active, not recruiting.
02
Drugs
etx101
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on NCT06112275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06112275.